Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM

Liana Spazzafumo, Emanuela Mensà, Giulia Matacchione, Tiziana Galeazzi, Lucia Zampini, Rina Recchioni, Fiorella Marcheselli, Francesco Prattichizzo, Roberto Testa, Roberto Antonicelli, Paolo Garagnani, Massimo Boemi, Massimiliano Bonafè, Anna Rita Bonfigli, Antonio Domenico Procopio, Fabiola Olivieri

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

β-Galactosidase (β-Gal) activity has been the most extensively utilized biomarker for the detection of cellular senescence. It can be measured also in plasma, and few recent evidence showed an altered plasmatic β-Gal activity in patients affected by some age-related diseases (ARDs). Since T2DM is one of the most common ARDs, we aimed to investigate if plasmatic β-Gal activity is modulated in T2DM patients and if "age" could affect such modulation. To gain mechanistic insights we paralleled this investigation with the evaluation of β-Gal activity in young and senescent endothelial cells (HUVECs) cultured in normo- and hyper-glycaemic environment. A significant age-related increase of plasmatic β-Gal activity was observed in healthy subjects (n. 230; 55-87 years), whereas the enzymatic activity was significantly reduced in T2DM patients (n. 230; 55-96 years) compared to healthy subjects. β-Gal activity detectable both in cells and in the culture medium was significantly increased in senescent cells compared to the younger ones, both under normoand hyper-glycaemic condition. However, the hyper-glycaemic condition was not associated with an increased β-Gal activity in milieu compared to normo-glycaemic condition. Overall our data reinforce the notion that plasmatic β-Gal activity could be a systemic biomarker of aging, whereas T2DM patients are characterized by a different age-releated trend.

Original languageEnglish
Pages (from-to)93338-93348
Number of pages11
JournalOncotarget
Volume8
Issue number55
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

beta-Galactosidase
Healthy Volunteers
Biomarkers
Galactosidases
Cell Aging
Culture Media
Endothelial Cells
Cell Culture Techniques

Keywords

  • Aging
  • Beta galactosidase activity
  • Cellular senescence
  • Gerotarget
  • Inflammaging
  • Type 2 diabetes

ASJC Scopus subject areas

  • Oncology

Cite this

Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM. / Spazzafumo, Liana; Mensà, Emanuela; Matacchione, Giulia; Galeazzi, Tiziana; Zampini, Lucia; Recchioni, Rina; Marcheselli, Fiorella; Prattichizzo, Francesco; Testa, Roberto; Antonicelli, Roberto; Garagnani, Paolo; Boemi, Massimo; Bonafè, Massimiliano; Bonfigli, Anna Rita; Procopio, Antonio Domenico; Olivieri, Fabiola.

In: Oncotarget, Vol. 8, No. 55, 01.11.2017, p. 93338-93348.

Research output: Contribution to journalArticle

@article{49011be4168f494e82aa37bd7f98f1c0,
title = "Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM",
abstract = "β-Galactosidase (β-Gal) activity has been the most extensively utilized biomarker for the detection of cellular senescence. It can be measured also in plasma, and few recent evidence showed an altered plasmatic β-Gal activity in patients affected by some age-related diseases (ARDs). Since T2DM is one of the most common ARDs, we aimed to investigate if plasmatic β-Gal activity is modulated in T2DM patients and if {"}age{"} could affect such modulation. To gain mechanistic insights we paralleled this investigation with the evaluation of β-Gal activity in young and senescent endothelial cells (HUVECs) cultured in normo- and hyper-glycaemic environment. A significant age-related increase of plasmatic β-Gal activity was observed in healthy subjects (n. 230; 55-87 years), whereas the enzymatic activity was significantly reduced in T2DM patients (n. 230; 55-96 years) compared to healthy subjects. β-Gal activity detectable both in cells and in the culture medium was significantly increased in senescent cells compared to the younger ones, both under normoand hyper-glycaemic condition. However, the hyper-glycaemic condition was not associated with an increased β-Gal activity in milieu compared to normo-glycaemic condition. Overall our data reinforce the notion that plasmatic β-Gal activity could be a systemic biomarker of aging, whereas T2DM patients are characterized by a different age-releated trend.",
keywords = "Aging, Beta galactosidase activity, Cellular senescence, Gerotarget, Inflammaging, Type 2 diabetes",
author = "Liana Spazzafumo and Emanuela Mens{\`a} and Giulia Matacchione and Tiziana Galeazzi and Lucia Zampini and Rina Recchioni and Fiorella Marcheselli and Francesco Prattichizzo and Roberto Testa and Roberto Antonicelli and Paolo Garagnani and Massimo Boemi and Massimiliano Bonaf{\`e} and Bonfigli, {Anna Rita} and Procopio, {Antonio Domenico} and Fabiola Olivieri",
year = "2017",
month = "11",
day = "1",
doi = "10.18632/oncotarget.21848",
language = "English",
volume = "8",
pages = "93338--93348",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "55",

}

TY - JOUR

T1 - Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM

AU - Spazzafumo, Liana

AU - Mensà, Emanuela

AU - Matacchione, Giulia

AU - Galeazzi, Tiziana

AU - Zampini, Lucia

AU - Recchioni, Rina

AU - Marcheselli, Fiorella

AU - Prattichizzo, Francesco

AU - Testa, Roberto

AU - Antonicelli, Roberto

AU - Garagnani, Paolo

AU - Boemi, Massimo

AU - Bonafè, Massimiliano

AU - Bonfigli, Anna Rita

AU - Procopio, Antonio Domenico

AU - Olivieri, Fabiola

PY - 2017/11/1

Y1 - 2017/11/1

N2 - β-Galactosidase (β-Gal) activity has been the most extensively utilized biomarker for the detection of cellular senescence. It can be measured also in plasma, and few recent evidence showed an altered plasmatic β-Gal activity in patients affected by some age-related diseases (ARDs). Since T2DM is one of the most common ARDs, we aimed to investigate if plasmatic β-Gal activity is modulated in T2DM patients and if "age" could affect such modulation. To gain mechanistic insights we paralleled this investigation with the evaluation of β-Gal activity in young and senescent endothelial cells (HUVECs) cultured in normo- and hyper-glycaemic environment. A significant age-related increase of plasmatic β-Gal activity was observed in healthy subjects (n. 230; 55-87 years), whereas the enzymatic activity was significantly reduced in T2DM patients (n. 230; 55-96 years) compared to healthy subjects. β-Gal activity detectable both in cells and in the culture medium was significantly increased in senescent cells compared to the younger ones, both under normoand hyper-glycaemic condition. However, the hyper-glycaemic condition was not associated with an increased β-Gal activity in milieu compared to normo-glycaemic condition. Overall our data reinforce the notion that plasmatic β-Gal activity could be a systemic biomarker of aging, whereas T2DM patients are characterized by a different age-releated trend.

AB - β-Galactosidase (β-Gal) activity has been the most extensively utilized biomarker for the detection of cellular senescence. It can be measured also in plasma, and few recent evidence showed an altered plasmatic β-Gal activity in patients affected by some age-related diseases (ARDs). Since T2DM is one of the most common ARDs, we aimed to investigate if plasmatic β-Gal activity is modulated in T2DM patients and if "age" could affect such modulation. To gain mechanistic insights we paralleled this investigation with the evaluation of β-Gal activity in young and senescent endothelial cells (HUVECs) cultured in normo- and hyper-glycaemic environment. A significant age-related increase of plasmatic β-Gal activity was observed in healthy subjects (n. 230; 55-87 years), whereas the enzymatic activity was significantly reduced in T2DM patients (n. 230; 55-96 years) compared to healthy subjects. β-Gal activity detectable both in cells and in the culture medium was significantly increased in senescent cells compared to the younger ones, both under normoand hyper-glycaemic condition. However, the hyper-glycaemic condition was not associated with an increased β-Gal activity in milieu compared to normo-glycaemic condition. Overall our data reinforce the notion that plasmatic β-Gal activity could be a systemic biomarker of aging, whereas T2DM patients are characterized by a different age-releated trend.

KW - Aging

KW - Beta galactosidase activity

KW - Cellular senescence

KW - Gerotarget

KW - Inflammaging

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85032948816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032948816&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21848

DO - 10.18632/oncotarget.21848

M3 - Article

AN - SCOPUS:85032948816

VL - 8

SP - 93338

EP - 93348

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 55

ER -